Madeleine A. Kane

Suggest Changes

Writes About:

Learn More
6016 Background: Vandetanib is a once-daily oral anticancer agent that selectively targets VEGF, EGF and RET receptor tyrosine kinases. We report preliminary results from an ongoing open-label phase(More)